Literature DB >> 12913217

Levetiracetam as a treatment for tardive dyskinesia: a case report.

Cameron L McGavin1, Vineeth John, William S Musser.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913217     DOI: 10.1212/01.wnl.0000073538.60021.50

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Levetiracetam in the treatment of vascular chorea: a case report.

Authors:  Marco D'Amelio; Graziella Callari; Matilde Gammino; Valentina Saia; Innocenzo Lupo; Giuseppe Salemi; Paolo Ragonese; Giovanni Savettieri
Journal:  Eur J Clin Pharmacol       Date:  2004-12-03       Impact factor: 2.953

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

3.  SV2 regulates neurotransmitter release via multiple mechanisms.

Authors:  Amy Nowack; Jia Yao; Kenneth L Custer; Sandra M Bajjalieh
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-11       Impact factor: 4.249

4.  Cotrafficking of SV2 and synaptotagmin at the synapse.

Authors:  Jia Yao; Amy Nowack; Patricia Kensel-Hammes; Richard G Gardner; Sandra M Bajjalieh
Journal:  J Neurosci       Date:  2010-04-21       Impact factor: 6.167

5.  Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.

Authors:  Amy Nowack; Erik B Malarkey; Jia Yao; Adam Bleckert; Jessica Hill; Sandra M Bajjalieh
Journal:  PLoS One       Date:  2011-12-29       Impact factor: 3.240

6.  Tardive dyskinesia in patients treated with atypical antipsychotics: case series and brief review of etiologic and treatment considerations.

Authors:  Jungjin Kim; Eric Macmaster; Thomas L Schwartz
Journal:  Drugs Context       Date:  2014-04-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.